Literature DB >> 24525466

Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.

Kristine M Erlandson1, Maryann OʼRiordan, Danielle Labbato, Grace A McComsey.   

Abstract

BACKGROUND: The aim was to determine the association between bone health and inflammation, T-cell activation, and monocyte activation among HIV-infected persons on stable antiretroviral therapy.
METHODS: We performed a cross-sectional analysis of all the subjects enrolling in the Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV trial with available skeletal assessments by dual-energy x-ray absorptiometry, inflammation, and immune activation markers. Analyses used were Wilcoxon rank-sum tests, Spearman correlation coefficients, and linear regression.
RESULTS: One hundred forty-two subjects were included: 78% men, 69% African American, median age 46.3 years, CD4 count 604 cells per microliter, and 77% with undetectable HIV-1 RNA. Twenty-three percent had osteopenia/osteoporosis at the hip, and 21% had this at the lumbar spine. Soluble vascular cell adhesion molecule-1 was correlated with hip (r = -0.22) and spine (r = -0.23) bone mineral density (BMD), and bone turnover markers (r = 0.20-0.33; all P < 0.05). No significant correlations were observed between the BMD and T-cell activation (%CD38HLA-DR on CD4 or CD8 T cells), monocyte activation (CD14CD16, sCD14, and sCD163), or inflammatory markers [interleukin (IL)-6, tumor necrosis factor-α, highly sensitive C-reactive protein, D-dimer, receptor activator of NF-kB ligand, osteoprotegerin, soluble tumor necrosis factor-RI and II]. In regression models including traditional bone risk factors, hip BMD was associated with age, race, and body mass index; spine BMD was associated with race, family history of hip fracture, trunk fat, tenofovir, and HIV RNA; bone resorption (c-terminal collagen crosslinks) was associated with intracellular adhesion molecule-1 and trunk fat; bone formation (P1NP) was associated with soluble vascular cell adhesion molecule-1, trunk and limb fat (P ≤ 0.05).
CONCLUSIONS: Future studies should evaluate the longitudinal association of the adhesion molecules to further elucidate potential contributory mechanisms of bone loss among HIV-infected persons on stable antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24525466      PMCID: PMC3927157          DOI: 10.1097/QAI.0000000000000005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  43 in total

Review 1.  Angiogenesis and bone repair.

Authors:  Richard A D Carano; Ellen H Filvaroff
Journal:  Drug Discov Today       Date:  2003-11-01       Impact factor: 7.851

Review 2.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

3.  B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease.

Authors:  Toshihisa Kawai; Takashi Matsuyama; Yoshitaka Hosokawa; Seicho Makihira; Makoto Seki; Nadeem Y Karimbux; Reginaldo B Goncalves; Paloma Valverde; Serge Dibart; Yi-Ping Li; Leticia A Miranda; Cory W O Ernst; Yuichi Izumi; Martin A Taubman
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

4.  Inflammatory markers and the risk of hip fracture: the Women's Health Initiative.

Authors:  Kamil E Barbour; Robert Boudreau; Michelle E Danielson; Ada O Youk; Jean Wactawski-Wende; Nancy C Greep; Andrea Z LaCroix; Rebecca D Jackson; Robert B Wallace; Douglas C Bauer; Matthew A Allison; Jane A Cauley
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

5.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

6.  Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Kathleen Melbourne; Belinda Ha; Todd T Brown; Anthony Bloom; Neal Fedarko; Paul E Sax
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

7.  Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.

Authors:  Michael T Yin; Don J McMahon; David C Ferris; Chiyuan A Zhang; Aimee Shu; Ronald Staron; Ivelisse Colon; Jeffrey Laurence; Jay F Dobkin; Scott M Hammer; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 8.  Control of RANKL gene expression.

Authors:  Charles A O'Brien
Journal:  Bone       Date:  2009-08-27       Impact factor: 4.398

9.  Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children.

Authors:  Allison C Ross; Mary Ann O'Riordan; Norma Storer; Vikram Dogra; Grace A McComsey
Journal:  Atherosclerosis       Date:  2010-04-24       Impact factor: 6.847

10.  Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

Authors:  Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.771

View more
  18 in total

1.  Effects of randomized rosuvastatin compared with placebo on bone and body composition among HIV-infected adults.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS       Date:  2015-01-14       Impact factor: 4.177

2.  Rosuvastatin Worsens Insulin Resistance in HIV-Infected Adults on Antiretroviral Therapy.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2015-07-08       Impact factor: 9.079

3.  Fractures Are Not Associated with CD8(+) T Cell Activation: An Analysis of the ACTG ALLRT Study.

Authors:  Michelle A Kendall; Katherine Tassiopoulos; Grace A McComsey; Michael T Yin
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-16       Impact factor: 2.205

4.  Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-16       Impact factor: 2.205

5.  Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.

Authors:  Charles S Venuto; Jihoon Lim; Susan Messing; Peter W Hunt; Grace A McComsey; Gene D Morse
Journal:  Antivir Ther       Date:  2018

6.  Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.

Authors:  L T Vernon; Plp Jayashantha; M M Chidzonga; M C Komesu; R G Nair; N W Johnson
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

7.  Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Authors:  Todd T Brown; Carlee Moser; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Theodoros Kelesidis; Otto Yang; Michael P Dubé; Robert L Murphy; James H Stein; Grace A McComsey
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

8.  Plasma Sclerostin in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; MaryAnn O'Riordan; Corrilynn O Hileman; Eric Rapaport; Danielle Labbato; Thomas B Campbell; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-27       Impact factor: 2.205

9.  Abnormal Bone Acquisition With Early-Life HIV Infection: Role of Immune Activation and Senescent Osteogenic Precursors.

Authors:  John S Manavalan; Stephen Arpadi; Shenthuraan Tharmarajah; Jayesh Shah; Chiyuan A Zhang; Marc Foca; Natalie Neu; David L Bell; Kyle K Nishiyama; Stavroula Kousteni; Michael T Yin
Journal:  J Bone Miner Res       Date:  2016-07-06       Impact factor: 6.741

Review 10.  Does systemic inflammation and immune activation contribute to fracture risk in HIV?

Authors:  Tara McGinty; Paria Mirmonsef; Patrick W G Mallon; Alan L Landay
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.